Pepmix CTL Generation for Broad Multiviral Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating virus-specific cytotoxic T lymphocytes (CTLs) are limited by the spectrum of viruses that can be targeted and the complexity of manufacturing processes, which are time-consuming and require infectious virus material, making it difficult to produce broad-spectrum CTLs for post-transplant viral infections.
Innovation Solution
A method involving the use of peptide mixtures (pepmixes) to stimulate peripheral blood mononuclear cells (PBMCs) with cytokines, allowing rapid generation of polyclonal CTLs specific for multiple viral antigens, including immunodominant and subdominant antigens, without the need for dendritic cells, and adaptable for clinical use as an 'off-the-shelf' antiviral agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods using infectious virus material and dendritic cells are used to generate virus-specific CTLs, then the CTLs can be generated with high specificity, but the manufacturing process becomes complex and time-consuming (10-12 weeks)
Solution Approach 1:
The patent extracts and eliminates the requirement for infectious virus material and dendritic cells from the manufacturing process. Instead, it uses synthetic peptide mixtures (pepmixes) that contain only the essential antigenic information needed to generate virus-specific CTLs, thereby simplifying the process while maintaining specificity and reducing manufacturing time to 2-3 weeks.
Solution Approach 2:
The patent creates simplified copies of viral antigens using synthetic peptide mixtures that replicate the essential immunogenic features of full viral proteins without requiring the complete infectious virus or complex dendritic cell processing. These peptide copies are sufficient to activate and expand virus-specific T cells.
2Ease of manufacture
If a single T cell line is generated to target multiple viruses, then the logistics of manufacture are simplified, but the spectrum of viruses that can be effectively targeted is limited due to antigenic competition
Solution Approach 1:
The patent segments the antigenic information into multiple distinct peptide mixtures, each targeting a specific virus or viral family. This allows the immune system to process and respond to multiple antigens simultaneously without competition, as each peptide mixture can be independently optimized and combined. The segmented approach enables broader viral coverage while maintaining manufacturing simplicity.
Solution Approach 2:
The patent creates a universal platform using peptide mixtures that can be customized to target any combination of viruses. The same basic methodology and cell culture system can be applied universally across different viral targets, allowing flexible adaptation to cover a broad spectrum of viruses while maintaining consistent manufacturing processes.
3Loss of time
If rapid approaches like streptamer selection or cytokine-based selection are used to produce T cell products, then manufacturing time is reduced, but the cost increases and large starting blood volumes are required
Solution Approach 1:
The patent uses inexpensive, stable synthetic peptide mixtures that can be easily prepared and stored without requiring complex reagents like streptamers or large volumes of cytokines. The peptides are disposable, stable reagents that eliminate the need for expensive proprietary selection technologies while reducing both material costs and blood volume requirements.
Data Source
AI summary
The present invention concerns methods of generating CTLs that are able to target at least one antigen from two or more viruses. The method includes exposing mixtures of peptides for different antigens to the same plurality of PBMCs and, at least in certain aspects, expanding the cells in the presence of IL4 and IL7.